Angiogenesis and Gastric Cancer

血管新生與胃癌

10.29833/FJS.201106.0001

陳炯年(Chiung-Nien Chen)

gastric cancer ； angiogenesis ； color/power doppler ultrasound ； vascularity index

Formosan Journal of Surgery

44卷3期（2011 / 06 / 01）

89 - 94

英文

胃癌不管在全世界或台灣都是非常重要的癌症。目前唯有手術切除才有機會根治。但仍約有四成病人術後復發而死亡。如何預防與延長此類病人之壽命爲目前之重要課題。血管新生與腫瘤之成長，與轉移有密切關係，藉由血管新生之研究，目前已開發出抗血管新生的藥物，搭酊化學治療藥物，已可延長轉移大腸癌病人之存活時間。但目前仍無足夠證據顯示抗血管新生治療對胃癌有效。由於抗血管新生的標把藥物仍持續開發中，期待有朝一日，胃癌的抗血管新生治療也能開花結果。本篇僅就腫瘤血管新生之生物現象，血管內皮生長因子之家族與胃癌的關係和幽門桿菌與胃癌血管新生之關係和抗血管新生治療在胃癌的現況做一簡介。

Gastric cancer has been one of the ten most frequent cancers and the second leading cause of cancer-related deaths in the world. In Taiwan, it is the fifth most common cause of cancer-related deaths, accounting for 6.3% of all cancer deaths. At present surgery is the only hope of cure but there are still about 40% of patients who die of recurrent disease. How to extend the patient's survival after ”curative” gastrectomy becomes a very important issue. Angiogenesis is a crucial phenomenon for tumor growth and metastasis and anti-angiogenic therapy has become one of targeted therapies for cancer. It is known that combined anti-angiogenic therapy and chemotherapy can prolong survival of patients with metastatic colorectal cancer, but, there is currently no evidence to show that this strategy works for gastric cancer.Development of new anti-angiogenic agents and biomarkers of efficacy is ongoing, and it is expected that anti-angiogenic therapy will be effective in coping with gastric cancer in the future. This mini-review is written to briefly introduce tumor angiogenesis and anti-angiogenic therapy in gastric cancer, also discussing the vascular endothelial growth factor family, and Helicobacter pylori and angiogenesis.